Vertex Pharmaceuticals Inc. / CRISPR Therapeutics AG
2015 · Co-Development · $2.6B · Complete
Announcement Sentiment
88
Strongly positive
Outcome Score
85
Worked — the deal delivered on its rationale.
Vertex and CRISPR Therapeutics entered a strategic collaboration to use CRISPR/Cas9 gene editing for hemoglobinopathies (sickle cell disease and beta-thalassemia). This led to the development and 2023 FDA approval of Casgevy (exagamglogene autotemcel), the first CRISPR-based gene therapy approved in the US.